A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy

Primary Membranous Nephropathy Clinical Trial

Official title:
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles and Preliminary Efficacy of Subcutaneous Injection of Recombinant Humanized Anti-CD20 Monoclonal Antibody in the Treatment of Primary Membranous Nephropathy

Status Recruiting

Clinical Trial Summary

This Phase I Clinical Study assessed the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles and Preliminary Efficacy of Subcutaneous Injection of Recombinant Humanized Anti-CD20 Monoclonal Antibody in the Treatment of Primary Membranous Nephropathy

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05668403
Study type	Interventional
Source	Shanghai Jiaolian Drug Research and Development Co., Ltd
Contact	Minghui Zhao
Phone	0086-13501243815
Email	mhzhao@bjmu.edu.cn
Status	Recruiting
Phase	Phase 1
Start date	March 2, 2023
Completion date	September 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05800873` - Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001	Phase 1
Recruiting	`NCT05514015` - Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy	Phase 4
Recruiting	`NCT05696613` - A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy	Phase 3
Active, not recruiting	`NCT04629248` - A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy	Phase 3
Recruiting	`NCT05862233` - A Clinical Study of MIL62 in Primary Membranous Nephropathy	Phase 3
Not yet recruiting	`NCT06120673` - REmission in Membranous Nephropathy International Trial (REMIT)	Phase 3
Recruiting	`NCT05398653` - A Clinical Study of MIL62 in Primary Membranous Nephropathy	Phase 1/Phase 2
Active, not recruiting	`NCT05136456` - Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy	Phase 2
Recruiting	`NCT05707377` - A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous Nephropathy	Phase 2/Phase 3